Ignite Creation Date:
2025-12-25 @ 2:25 AM
Ignite Modification Date:
2026-01-12 @ 2:49 PM
Study NCT ID:
NCT03142334
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-11-13
First Post:
2017-05-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-06-09
Start Date Type:
ACTUAL
Primary Completion Date:
2020-12-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12-28
Completion Date Type:
ESTIMATED
First Submit Date:
2017-05-03
First Submit QC Date:
None
Study First Post Date:
2017-05-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-11-29
Results First Submit QC Date:
None
Results First Post Date:
2021-12-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-08
Last Update Post Date:
2024-11-13
Last Update Post Date Type:
ACTUAL